Analyst Reco. G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Market Closed - Nasdaq Other stock markets 21:30:01 06/05/2024 BST			5-day change	1st Jan Change
4.27 ^USD	-4.90%		+14.78%	+40.00%

05-01	Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
05-01	Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	02-28	MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating	02-13	MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating	02-13	MT
JPMorgan Downgrades G1 Therapeutics to Underweight From Neutral	06/10/23	MT
Raymond James Adjusts Price Target on G1 Therapeutics to $8 From $24, Maintains Outperform Rating	04/05/23	MT
Needham Cuts Price Target on G1 Therapeutics to $18 From $31, Maintains Buy Rating	14/02/23	MT
HC Wainwright Lowers Price Target on G1 Therapeutics to $11 From $34, Maintains Buy Rating	14/02/23	MT
EF Hutton Adjusts Price Target on G1 Therapeutics to $19 From $35, Maintains Buy Rating	13/02/23	MT
JPMorgan Upgrades G1 Therapeutics to Neutral From Underweight, Adjusts Price Target to $10 From $7	30/01/23	MT
EF Hutton Initiates G1 Therapeutics at Buy With $35 Price Target	05/01/23	MT
G1 Therapeutics Says Phase 2 Trial Shows Objective Response Rate of 40% in Patients With Bladder Cancer	04/01/23	MT
Needham Adjusts Price Target on G1 Therapeutics to $31 From $32, Maintains Buy Rating	03/01/23	MT
HC Wainwright Adjusts G1 Therapeutics Price Target to $57 From $67, Maintains Buy Rating	02/11/22	MT
Wedbush Lifts Price Target on G1 Therapeutics to $25 From $20, Citing Trilaciclib Potential, Keeps Outperform Rating	16/09/22	MT
Needham Adjusts Price Target on G1 Therapeutics to $32 From $42, Reiterates Buy Rating	04/08/22	MT
Needham Adjusts G1 Therapeutics' Price Target to $42 from $44, Keeps Buy Rating	05/05/22	MT
Wedbush Cuts G1 Therapeutics' Price Target to $20 From $24, Citing Cost of Capital; Outperform Rating Kept	05/05/22	MT
Raymond James Adjusts Price Target on G1 Therapeutics to $24 from $41, Keeps Outperform Rating	04/11/21	MT
HC Wainwright Adjusts G1 Therapeutics' Price Target to $71 from $78, Keeps Buy Rating	04/11/21	MT
JP Morgan Downgrades G1 Therapeutics to Underweight Rating From Neutral, Adjusts Price Target to $19 From $20	04/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Analyst Reco.

Filters